

SUPPLEMENT NO. 1 DATED 20 APRIL 2023 TO THE PROSPECTUS DATED 16 MARCH 2023



(incorporated as a société anonyme under the laws of the Hellenic Republic)

This supplement (the "**Prospectus Supplement**") is supplemental to, forms part of and must be read and construed in conjunction with, the prospectus (the "**Prospectus**"), within the meaning of Article 6 and Article 10 of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") of Attica Bank S.A. ("**Attica Bank**" or the "**Issuer**"), which comprises (i) a summary (the "**Summary**"), as approved by the Hellenic Capital Market Commission (the "**HCMC**") on 16 March 2023, (ii) a registration document, as approved by the HCMC on 17 November 2022, as supplemented by way of a supplement, as approved by the HCMC on 16 March 2023 (the "**Registration Document**"), and (iii) a securities note (the "**Securities Note**"), as approved by the HCMC on 16 March 2023, relating to (i) the offering to the public of up to 35,062,731 new ordinary registered shares with voting rights and a nominal value of €0.05 each in the share capital of the Issuer (the "**New Ordinary Shares**") to be issued by Attica Bank (the "**Public Offering**"); and (ii) the admission to trading (the "**Admission**") of the New Ordinary Shares on the Main Market of the Regulated Securities Market of the Athens Stock Exchange ("**ATHEX**").

Withdrawal right

Investors who have already agreed to subscribe for New Ordinary Shares before the date of the Prospectus Supplement shall have the right, exercisable within two (2) working days after the publication of the Prospectus Supplement, to withdraw their subscription for such New Ordinary Shares. The last day on which such right of withdrawal can be exercised shall be 24 April 2023.

In particular:

- (a) the right of withdrawal is only granted to those investors who had already agreed to subscribe for New Ordinary Shares before the Prospectus Supplement was published;
- (b) the period in which investors can exercise their right of withdrawal shall commence on 21 April 2023 and shall expire on 24 April 2023, at 3:00 p.m., Athens time;
- (c) investors may contact the Participants of the Securities Accounts (or financial intermediaries under the meaning of Part I Section I of the Rulebook of the Hellenic Central Securities Depository and art.2d of Regulation (EU) 2017/1129 acting on their behalf, indirectly through such Participants) or file a relevant request at branches of Attica Bank, during business days and hours, should they wish to exercise the right of withdrawal; and
- (d) in the event of subscriptions being submitted through financial intermediaries acting indirectly for their investors, the financial intermediaries shall inform the investors of the Prospectus Supplement as published, where and when it has been published and shall assist them solely in exercising their right to withdraw acceptances where applicable.

Investing in the New Ordinary Shares involves risks. Prospective investors should read the entire Prospectus and, in particular, the "Risk Factors" beginning on page 15 of the Registration Document and on page 11 of the Securities Note, when considering an investment in the New Ordinary Shares.

The Prospectus Supplement constitutes a supplement for the purposes of Article 23(1) of the Prospectus Regulation and of Delegated Regulation (EU) 2019/979 of 14 March 2019 and will be valid for a period of twelve (12) months from its approval by the board of directors of the HCMC. In the event of any significant new factor, material mistake or material inaccuracy relating to the information included in the Prospectus, as supplemented by the Prospectus Supplement, which may affect the assessment of the New Ordinary Shares and which arises or is noted between the time when the Prospectus Supplement is approved and the closing of the Public Offering or the time when the trading of the New Ordinary Shares begins, whichever occurs later, a new supplement shall be published in accordance with Article 23 of the Prospectus Regulation and of Delegated Regulation (EU) 2019/979, as applicable, without undue delay, in accordance with at least the same arrangements made for the publication of the Prospectus. To the extent that there is any inconsistency between (a) any statement in the Prospectus Supplement or any statement incorporated by reference into the Prospectus by the Prospectus Supplement and (b) any other statement in, or incorporated by reference into, the Prospectus, the Prospectus Supplement will prevail.

The board of directors of the HCMC approved the Prospectus Supplement on 20 April 2023 only in connection with the information furnished to investors, as required under the Prospectus Regulation, and Delegated Regulation (EU) 2019/980 of 14 March 2019, and only as meeting the standards of completeness, comprehensibility and consistency provided for in

the Prospectus Regulation. The approval of the Prospectus Supplement by the HCMC shall not be considered as an endorsement of Attica Bank or of the quality of the Attica Bank's securities. Prospective investors should make their own assessment as to the suitability of investing in Attica Bank's securities.

The date of the Prospectus Supplement is 20 April 2023.

TABLE OF CONTENTS

Section	Page
A. DEFINITIONS AND GLOSSARY.....	3
B. PERSONS RESPONSIBLE, THIRD PARTY INFORMATION, EXPERTS' REPORTS AND COMPETENT AUTHORITY APPROVAL.....	3
1 SUMMARY	5
1 ΠΕΡΙΛΗΠΤΙΚΟ ΣΗΜΕΙΩΜΑ	6
2 REGISTRATION DOCUMENT	7
3 SECURITIES NOTE.....	9

A. DEFINITIONS AND GLOSSARY

Terms given a defined meaning in the Prospectus shall, unless the context otherwise requires, have the same meaning when used in the Prospectus Supplement.

B. PERSONS RESPONSIBLE, THIRD PARTY INFORMATION, EXPERTS' REPORTS AND COMPETENT AUTHORITY APPROVAL

1. GENERAL INFORMATION

The drafting and distribution of the Prospectus Supplement have been made in accordance with the provisions of applicable law. The Prospectus Supplement includes all information required by the Prospectus Regulation, Delegated Regulation (EU) 2019/980 of 14 March 2019, the applicable provisions of Law 4706/2020 and the enabling relevant decisions of the HCMC, relevant to Attica Bank and its securities.

Prospective investors seeking additional information and clarifications related to the Prospectus Supplement may contact Attica Bank, during working days and hours, at 23, Omirou Street, 106-72 Athens, Greece (Ms Eleni Vrettou, Chief Executive Officer +30 210 3667310 and Ms Valerie Skoubas, Chief Financial Officer, +30 210 3667058). In the event of financial intermediaries or Participants acting indirectly for their investors, the above information and clarifications shall be provided to the relevant intermediaries.

2. THIRD-PARTY INFORMATION

Any information included in the Prospectus Supplement deriving from third-party sources is marked as such, it identifies the source of any such information that has been reproduced accurately and, so far as Attica Bank is aware and is able to ascertain from information published by such third parties, no facts have been omitted which would render the reproduced information inaccurate or misleading.

Any market data used in the Prospectus Supplement has been obtained from Attica Bank's internal surveys, reports and studies, where appropriate, as well as market research, publicly available information and industry publications, including, without limitation, reports, and press releases prepared and issued by the International Monetary Fund, the Hellenic Statistical Authority, the central bank of Greece (the "**Bank of Greece**"), the Hellenic Bank Association, Eurostat, the European Commission, the Public Debt Management Agency and the ATHEX, as well as the Stability Programme of the Hellenic Republic for the period 2020 to 2023, and the Monthly Statistical Bulletins of the ECB. Market research, publicly available information and industry publications generally state that the information they contain has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. Attica Bank accepts responsibility for accurately extracting and reproducing the same but accepts no further or other responsibility in respect of the accuracy or completeness of such information.

Unless explicitly provided otherwise or the context otherwise requires, all statistical data pertaining to Attica Bank's market position that is indicated to be derived from the Bank of Greece are the product of Attica Bank's internal calculations and analysis using data provided by the Bank of Greece.

3. APPROVAL BY THE COMPETENT AUTHORITY

The Prospectus Supplement was approved on 20 April 2023 by the board of directors of the HCMC (3-5 Ippokratous Street, 10679 Athens, Greece, telephone number: +30 210 3377100, <http://www.hcmc.gr/>), as competent authority pursuant to the Prospectus Regulation and Law 4706/2020, as applicable,. The board of directors of the HCMC approved the Prospectus Supplement only as meeting the standards of completeness, comprehensibility and consistency provided for in the Prospectus Regulation, and the approval shall not be considered as an endorsement of Attica Bank or of the quality of Attica Bank's securities. In making an investment decision, prospective investors must rely upon their own examination and analysis as to their investment in Attica Bank's securities.

4. PERSONS RESPONSIBLE

The natural persons who are responsible for drawing up the Prospectus Supplement, on behalf of Attica Bank, and are responsible for the Prospectus Supplement, as per the above, are Ms Eleni Vrettou, Chief Executive Officer +30 210 3667310 and Ms Valerie Skoubas, Chief Financial Officer, +30 210 3667058. Their address

is the address of Attica Bank: 23, Omirou Street, 106-72 Athens, Greece. Attica Bank. Attica Bank, the members of the Board and the natural persons who are responsible for drawing up the Prospectus Supplement on Attica Bank's behalf are responsible for its contents pursuant to Article 60 of Law 4706/2020.

For further details on the composition of the members of the Board see section 8 "*Administrative Management, Supervisory Bodies and Senior Management—Management and corporate governance of Attica Bank—Board of Directors*" of the Registration Document.

Attica Bank, the members of the Board and the natural persons who are responsible for drawing up the Prospectus Supplement on Attica Bank's behalf declare that they have been informed and agree with the content of the Prospectus Supplement and certify that, after they exercised due care for the purpose, the information contained herein, to the best of their knowledge, is true, the Prospectus Supplement makes no omission likely to affect its import, and it has been drafted in accordance with the provisions of the Prospectus Regulation, Delegated Regulation (EU) 2019/980 of 14 March 2019, Delegated Regulation (EU) 2019/979 of 14 March 2019 and the provisions of Law 4706/2020, as applicable.

5. DISTRIBUTION OF THE PROSPECTUS SUPPLEMENT

The Prospectus Supplement will be made available to investors, in accordance with Article 21, paragraph 2 of the Prospectus Regulation, in electronic form on the following websites:

- Attica Bank: <https://www.atticabank.gr/en/investors/prospectuses/prospectus-2023>
- ATHEX: <http://www.helex.gr/el/web/guest/company-prospectus>

In addition, printed copies of the Prospectus Supplement, will be made available to investors at no extra cost, if requested, at the address of Attica Bank: 23, Omirou Street, 106-72 Athens, Greece. According to Article 21(5) of the Prospectus Regulation, HCMC publishes on its website (http://www.hcmc.gr/el_GR/web/portal/elib/deltia) the prospectuses approved.

1 SUMMARY

1. The information set out below supplements section 2.1 (*Who is the Issuer of the New Ordinary Shares?*) of the Summary. The third paragraph under the heading "*Major Shareholders*" shall be deleted in its entirety and replaced with the following:

*"On 20 April 2023, HFSF, Thrivest Holding Ltd ("**Thrivest**") and Pancreta Bank S.A. ("**Pancreta Bank**") and the Issuer entered into an investment agreement on the commercial terms for the participation by the HFSF, Thrivest and Pancreta Bank in the Share Capital Increase and their investment in the Issuer (the "**Investment Agreement**"). It should be noted that TMEDE is not party to the Investment Agreement and has notified the Issuer that it is not intending to participate in the Share Capital Increase. The execution and the terms of the Investment Agreement were approved by the Board of Directors of the Issuer on 19 April 2023.*

Pursuant to the Investment Agreement, HFSF, Thrivest and Pancreta Bank are committed to participate in the Share Capital Increase under the provisions of the legislative framework including the HFSF Law as follows: (a) the HFSF commits to invest up to €329,000,000 in total, subject to the condition that the Share Capital Increase is fully covered, as per the HFSF Law; (b) Thrivest commits to invest up to €30,000,000 in total, through acquisition of new shares in the Issuer for which the pre-emption rights were not subscribed subject to the condition that the HFSF exercises its pre-emption rights in the Share Capital Increase in full, and (c) Pancreta commits to invest up to €34,000,000 in total, through acquisition of new shares in the Issuer for which the pre-emption rights were not subscribed, subject to the condition that the HFSF exercises its pre-emption rights in the Share Capital Increase in full.

On 20 April 2023, the Issuer has published an announcement relating to the Investment Agreement.

As at 20 April 2023 and Admission, respectively, there will be no options or other dilutive instruments in issue. Other than the Investment Agreement, Attica Bank is not aware of any arrangement, the operation of which may, at a subsequent date, result in a change in control of Attica Bank.

(a) The table below sets out Attica Bank's shareholding structure after the Share Capital Increase, under the following assumptions: (a) e-EFKA does not exercise its pre-emption rights and does not participate in the Share Capital Increase at all; (b) TMEDE does not exercise its pre-emption rights and does not participate in the Share Capital Increase at all; (c) in accordance with the Investment Agreement the HFSF subscribes for €329 million of New Ordinary Shares, Thrivest subscribes for €30 million of New Ordinary Shares and Pancreta Bank subscribes for €34 million of New Ordinary Shares and (d) any remaining New Ordinary Shares are not subscribed, hence the Share Capital Increase is not subscribed for in full. It is noted that this scenario is hypothetical and based on assumptions which may not come true:

Shareholder⁽¹⁾	Number of Ordinary Shares	Percentage of Ordinary Shares
HFSF	31,300,851	80.09%
TMEDE	2,005,278	5.13%
Thrivest	2,222,222	5.69%
Pancreta Bank	2,518,518	6.44%
e-EFKA	837,390	2.14%
Other Shareholders (<5%)	198,041	0.51%
Total	39,082,300	100%

⁽¹⁾ One Ordinary Share corresponds to one voting right.

Source: Issuer's analysis – Based on shareholder register as at the date of the Prospectus Supplement.

*It is noted that the non subscription of the Share Capital Increase constitutes a risk factor; for more information please refer to section section 2.3 of the Summary (*What are the key risks that are specific to the Issuer?*).*

(b) The table below sets out Attica Bank's shareholding structure after the Share Capital Increase, under the following assumptions: (a) e-EFKA does exercise its pre-emption rights with respect to the totality of the Ordinary Shares it holds, (b) TMEDE does not exercise its pre-emption rights and does not participate in the Share Capital Increase at all; (c) The Board of Directors receives and satisfies applications for subscriptions from various new applicants-potential shareholders, covering the total of the unsubscribed shares without exceeding 5% of the Issuer Share Capital for each applicant, and (d) in accordance with the Investment Agreement the HFSF subscribes for €329 million, Thrivest subscribes for €30 million and Pancreta Bank subscribes for €34 million of New Ordinary Shares, hence the Share Capital Increase is subscribed for in full. It is noted that the above scenario is hypothetical and based on assumptions that may not come true:

<i>Shareholder⁽¹⁾</i>	<i>Number of Ordinary Shares</i>	<i>Percentage of Ordinary Shares</i>
HFSF	31,300,851	69.51%
TMEDE	2,005,278	4.45%
Thrivest	2,222,222	4.93%
Pancreta	2,518,518	5.59%
e-EFKA	3,781,991	8.40%
Other Shareholders (<5%)	3,205,059	7.12%
Total	45,033,921	100%

⁽¹⁾ One Ordinary Share corresponds to one voting right.

Source: Issuer's analysis – Based on shareholder register as at the date of the Prospectus Supplement.

It is noted that the non subscription of the Share Capital Increase constitutes a risk factor; for more information please refer to section 2 of the Summary (What are the key risks that are specific to the Issuer?).

2. The information set out below supplements section 2.3 (What are the key risks that are specific to the Issuer?) of the Summary. Paragraph (a) shall be deleted in its entirety and replaced with the following:

" (a) the Issuer expects that a successful completion of the Share Capital Increase will enable the Issuer to significantly increase its regulatory capital ratios whilst decreasing its NPE ratio in accordance with its business plan. However, other than the commitments contemplated under the Investment Agreement, there are no commitments nor any guarantee towards the subscription of the New Ordinary Shares and the Public Offering is not subject to an underwriting agreement; accordingly, there can be no assurance that the Share Capital Increase will be subscribed in full or at all. If the Share Capital Increase is not fully subscribed, the existing issued share capital will only be increased up to the amount actually subscribed and paid for, in accordance with article 28 paragraph 1 of Law 4548/2018. Failure to raise the equity needed for the restoration of the Issuer's regulatory capital ratios through the Share Capital Increase or future capital actions, may force the regulatory authorities to subject Attica Bank to resolution measures and/or Attica Bank to request public financial support which will have a material adverse effect on its Shareholders (or holders of other capital instruments) and/or its business, financial condition, results of operations and prospects"

3. The information set out below supplements section 4.1 (Under which conditions and timetable can I invest in the New Ordinary Shares?) of the Summary. The final paragraph under the heading "General terms and conditions" shall be deleted in its entirety and replaced with the following:

" Other than the Investment Agreement (as defined below), as disclosed in the Registration Document, the Issuer has no indication of whether the Major Shareholders or members of the Issuer's management, supervisory or administrative bodies intend to subscribe in the Public Offering, or whether any person intends to subscribe for more than five per cent (5%) of the New Ordinary Shares."

4. The information set out below supplements section 4.1 (Under which conditions and timetable can I invest in the New Ordinary Shares?) of the Summary. The timetable included under the heading "Expected timetable" shall be deleted in its entirety and replaced with the following:

<i>Date</i>	<i>Event</i>
30 December 2022	EGM approves the Share Capital Increase
16 March 2023	Approval of Prospectus by the HCMC
16 March 2023	Publication of announcement regarding the availability of the Prospectus in the Daily Statistical Bulletin of the ATHEX and on the Issuer's website.
16 March 2023	Publication of the Prospectus
16 March 2023	ATHEX approval for the commencement of trading and exercise of pre-emptive rights*
16 March 2023	Announcement of the date of detachment of the pre-emptive rights and the period of trading and exercise of pre-emptive rights
24 March 2023	Last day of trading of Existing Ordinary Shares with pre-emptive rights
27 March 2023	Detachment of pre-emptive rights and adjustment of share price

28 March 2023	<i>Record date for the beneficiaries of pre-emptive rights</i>
29 March 2023	<i>Crediting of pre-emptive rights on the Securities Accounts of the beneficiaries</i>
30 March 2023	<i>Commencement of trading and exercise of pre-emptive rights</i>
19 April 2023	<i>Last day of trading of pre-emptive rights</i>
20 April 2023	<i>Approval of Prospectus Supplement by the HCMC</i>
20 April 2023	<i>Publication of announcement regarding the availability of the Prospectus Supplement in the Daily Statistical Bulletin of the ATHEX and on the Issuer's website</i>
20 April 2023	<i>Publication of the Prospectus Supplement</i>
21 April 2023	<i>Commencement of exercise of the right of withdrawal</i>
24 April 2023	<i>Last day of exercise of the right of withdrawal</i>
24 April 2023	<i>Last day of exercise of pre-emptive rights</i>
25 April 2023	<i>Allocation and disposal of any unsubscribed New Ordinary Shares</i>
26 April 2023	<i>Certification of payment of the Share Capital Increase</i>
26 April 2023	<i>Announcement on the subscription of the Share Capital Increase</i>
27 April 2023	<i>ATHEX approval for the admission to trading of the New Ordinary Shares *</i>
28 April 2023	<i>Commencement of trading of the New Ordinary Shares</i>

** Subject to the competent ATHEX committee meeting on that date."*

1 ΠΕΡΙΛΗΠΤΙΚΟ ΣΗΜΕΙΩΜΑ

1. Οι πληροφορίες που παρατίθενται κατωτέρω συμπληρώνουν την ενότητα 2.1 (Ποιος είναι ο Εκδότης των Νέων Κοινών Μετοχών) του Περιληπτικού Σημειώματος. Η τρίτη παράγραφος υπό τον τίτλο «Κύριοι Μέτοχοι» διαγράφεται στο σύνολό της και αντικαθίσταται ως εξής:

Στις 20 Απριλίου 2023, το ΤΧΣ, η Thrivest Holding Ltd ("Thrivest"), η Pancreta Bank S.A. ("Pancreta Bank") και ο Εκδότης συνήψαν επενδυτική συμφωνία σχετικά με τους εμπορικούς όρους για τη συμμετοχή του ΤΧΣ, της Thrivest και της Pancreta Bank στην Αύξηση Μετοχικού Κεφαλαίου και την επένδυσή τους στον Εκδότη (η "Επενδυτική Συμφωνία"). Σημειώνεται ότι το ΤΜΕΔΕ δεν είναι συμβαλλόμενο μέρος της Επενδυτικής Συμφωνίας και έχει γνωστοποιήσει στον Εκδότη ότι δεν προτίθεται να συμμετάσχει στην Αύξηση Μετοχικού Κεφαλαίου. Η υπογραφή και οι όροι της Επενδυτικής Συμφωνίας εγκρίθηκαν από το Διοικητικό Συμβούλιο του Εκδότη στις 19 Απριλίου 2023.

Σύμφωνα με την Επενδυτική Συμφωνία το ΤΧΣ, η Thrivest και η Pancreta Bank δεσμεύονται να συμμετάσχουν στην Αύξηση Μετοχικού Κεφαλαίου σύμφωνα με τις διατάξεις του νομοθετικού πλαισίου, συμπεριλαμβανομένου του Νόμου του ΤΧΣ ως ακολούθως: (α) το ΤΧΣ δεσμεύεται να επενδύσει συνολικά έως €329.000.000, υπό την προϋπόθεση ότι η Αύξηση Μετοχικού Κεφαλαίου θα καλυφθεί πλήρως, σύμφωνα με το Νόμο του ΤΧΣ, (β) η Thrivest δεσμεύεται να επενδύσει έως €30.000.000 συνολικά, μέσω της απόκτησης νέων μετοχών του Εκδότη για τις οποίες δεν έχουν εξασκηθεί τα δικαιώματα προτίμησης, υπό την προϋπόθεση ότι το ΤΧΣ θα εξασκήσει πλήρως τα δικαιώματα προτίμησης του στην Αύξηση Μετοχικού Κεφαλαίου και (γ) η Pancreta δεσμεύεται να επενδύσει μέχρι €34.000.000 συνολικά, μέσω της απόκτησης νέων μετοχών του Εκδότη για τις οποίες δεν έχουν εξασκηθεί τα δικαιώματα προτίμησης, υπό την προϋπόθεση ότι το ΤΧΣ θα εξασκήσει πλήρως τα δικαιώματα προτίμησης του στην Αύξηση Μετοχικού Κεφαλαίου.

Στις 20 Απριλίου 2023, ο Εκδότης δημοσίευσε ανακοίνωση σε σχέση με την Επενδυτική Συμφωνία.

Κατά την 20η Απριλίου 2023 και την Εισαγωγή, αντιστοίχως, δεν θα υπάρχουν δικαιώματα προτίμησης ή άλλες αξίες σε έκδοση που μειώνουν τη συμμετοχή στο μετοχικό κεφάλαιο. Εκτός από την Επενδυτική Συμφωνία, δεν υπάρχει γνωστή στην Attica Bank συμφωνία, της οποίας η εφαρμογή θα μπορούσε, σε μεταγενέστερη ημερομηνία, να επιφέρει αλλαγές όσον αφορά τον έλεγχο της Attica Bank.

α. Στον παρακάτω πίνακα παρατίθεται η μετοχική σύνθεση της Attica Bank μετά την Αύξηση, υπό τις ακόλουθες παραδοχές: (α) ο e-ΕΦΚΑ δεν θα ασκήσει τα δικαιώματα προτίμησης του και δεν θα συμμετάσχει στην Αύξηση καθόλου, (β) το ΤΜΕΔΕ δεν θα ασκήσει τα δικαιώματα προτίμησης του και δεν θα συμμετάσχει στην Αύξηση, (γ) σύμφωνα με την Επενδυτική Συμφωνία, το ΤΧΣ θα συμμετάσχει με κάλυψη €329 εκατ. Νέων Κοινών Μετοχών, η Thrivest θα συμμετάσχει με κάλυψη €30 εκατ. Νέων Κοινών Μετοχών και η Παγκρήτεια Τράπεζα, θα συμμετάσχει με κάλυψη €34 εκατ. Νέων Κοινών Μετοχών και (δ) οι εναπομείνουσες Νέες Κοινές Μετοχές δεν θα καλυφθούν και ως εκ τούτου η Αύξηση δεν θα καλυφθεί πλήρως. Σημειώνεται ότι το παραπάνω σενάριο είναι υποθετικό και βασίζεται σε παραδοχές που ενδεχομένως να μην επαληθευτούν:

Μέτοχος ⁽¹⁾	Αριθμός Κοινών Μετοχών	Ποσοστό % επί των Κοινών Μετοχών
ΤΧΣ	31.300.851	80,09%
ΤΜΕΔΕ	2.005.278	5,13%
Thrivest	2.222.222	5,69%
Παγκρήτεια Τράπεζα	2.518.518	6,44%
e-ΕΦΚΑ	837.390	2,14%
Λοιποί Μέτοχοι (<5%)	198.041	0,51%
Σύνολο	39.082.300	100%

(1) Μια Κοινή Μετοχή αντιστοιχεί σε ένα δικαίωμα ψήφου.

Πηγή: Στοιχεία του Εκδότη - Με βάση το μετοχολόγιο κατά την ημερομηνία του Συμπληρώματος Ενημερωτικού Δελτίου.

Σημειώνεται ότι η μη κάλυψη της Αύξησης αποτελεί επενδυτικό κίνδυνο. Για περισσότερες πληροφορίες ανατρέξτε στην ενότητα 2.3 του Περιληπτικού Σημειώματος (Ποιοι είναι οι βασικοί κίνδυνοι που αφορούν ειδικά τον Εκδότη).

β.Στον παρακάτω πίνακα παρατίθεται η μετοχική σύνθεση της Attica Bank μετά την Αύξηση, υπό τις ακόλουθες παραδοχές: (α) ο e-ΕΦΚΑ θα ασκήσει τα δικαιώματα προτίμησής του για το σύνολο των Κοινών Μετοχών που κατέχει, (β) το ΤΜΕΔΕ δεν θα ασκήσει τα δικαιώματα προτίμησής του και δεν θα συμμετάσχει στην Αύξηση, (γ) το Διοικητικό Συμβούλιο του Εκδότη λαμβάνει και αποδέχεται αιτήσεις κάλυψης από διάφορους νέους αιτούντες – πιθανούς μετόχους, που καλύπτουν το σύνολο των αδιάθετων μετοχών, χωρίς να υπερβαίνει το 5% του Μετοχικού Κεφαλαίου του Εκδότη για κάθε αιτούντα, (δ) σύμφωνα με την Επενδυτική Συμφωνία, το ΤΧΣ θα συμμετάσχει με κάλυψη €329 εκατ. Νέων Κοινών Μετοχών, η Thrivest θα συμμετάσχει με κάλυψη €30 εκατ. Νέων Κοινών Μετοχών και η Παγκρήτια Τράπεζα, θα συμμετάσχει με κάλυψη €34εκατ. Νέων Κοινών Μετοχών και (δ) ως εκ τούτου η Αύξηση θα καλυφθεί πλήρως. Σημειώνεται ότι το παραπάνω σενάριο είναι υποθετικό και βασίζεται σε παραδοχές που ενδεχομένως να μην επαληθευτούν:

Μέτοχος⁽¹⁾	Αριθμός Κοινών Μετοχών	Ποσοστό % επί των Κοινών Μετοχών
<i>ΤΧΣ</i>	<i>31.300.851</i>	<i>69,51%</i>
<i>ΤΜΕΔΕ</i>	<i>2.005.278</i>	<i>4,45%</i>
<i>Thrivest</i>	<i>2.222.222</i>	<i>4,93%</i>
<i>Παγκρήτια Τράπεζα</i>	<i>2.518.518</i>	<i>5,59%</i>
<i>e-ΕΦΚΑ</i>	<i>3.781.991</i>	<i>8,40%</i>
<i>Λοιποί Μέτοχοι (<5%)</i>	<i>3.205.059</i>	<i>7,12%</i>
Σύνολο	45.033.921	100%

(1) .Μια Κοινή Μετοχή αντιστοιχεί σε ένα δικαίωμα ψήφου.

Πηγή: Στοιχεία του Εκδότη - Με βάση το μετοχολόγιο κατά την ημερομηνία του Συμπληρώματος Ενημερωτικού Δελτίου.

Σημειώνεται ότι η μη κάλυψη της Αύξησης αποτελεί επενδυτικό κίνδυνο. Για περισσότερες πληροφορίες ανατρέξτε στην ενότητα 2 του Περιληπτικού Σημειώματος (Ποιοι είναι οι βασικοί κίνδυνοι που αφορούν ειδικά τον Εκδότη).

2. Οι πληροφορίες που παρατίθενται κατωτέρω συμπληρώνουν την ενότητα 2.3 (Ποιοι είναι οι βασικοί κίνδυνοι που αφορούν ειδικά τον Εκδότη) του Περιληπτικού Σημειώματος. Η παράγραφος (α) διαγράφεται στο σύνολό της και αντικαθίσταται ως εξής:

“α. Ο Εκδότης αναμένει ότι η επιτυχής ολοκλήρωση της Αύξησης Μετοχικού Κεφαλαίου θα επιτρέψει στον Εκδότη να αυξήσει σημαντικά τους δείκτες εποπτικών κεφαλαίων του, μειώνοντας παράλληλα τον δείκτη των μη εξυπηρετούμενων ανοιγμάτων του (NPE) σύμφωνα με το επιχειρηματικό του σχέδιο. Ωστόσο, εκτός από τις δεσμεύσεις που προβλέπονται στην Επενδυτική Συμφωνία, δεν υπάρχουν δεσμεύσεις ούτε εγγυήσεις για την κάλυψη των Νέων Κοινών Μετοχών και η Δημόσια Προσφορά δεν υπόκειται σε σύμβαση αναδοχής. Κατά

συνέπεια, δεν μπορεί να υπάρξει καμία διαβεβαίωση ότι η Αύξηση Μετοχικού Κεφαλαίου θα καλυφθεί πλήρως ή και καθόλου. Εάν η Αύξηση του Μετοχικού Κεφαλαίου δεν καλυφθεί πλήρως, το υφιστάμενο εκδοθέν μετοχικό κεφάλαιο του Εκδότη θα αυξηθεί μόνο έως του ποσού που έχει πράγματι καλυφθεί και καταβληθεί, σύμφωνα με το άρθρο 28 παράγραφος 1 του Ν. 4548/2018. Η μη έγκαιρη επίτευξη των εφαρμοστέων εποπτικών δεικτών κεφαλαιακής επάρκειας μέσω της επιτυχούς ολοκλήρωσης της Αύξησης Μετοχικού Κεφαλαίου ή οποιασδήποτε άλλης ενέργειας κεφαλαιακής ενίσχυσης, ενδέχεται να οδηγήσει στην εφαρμογή ενός ή περισσότερων μέτρων εξυγίανσης και/ή την υποβολή αιτήματος από την Attica Bank για λήψη κρατικής οικονομικής ενίσχυσης, γεγονός το οποίο ενδέχεται να έχει ουσιώδη δυσμενή επίπτωση στους Μετόχους (ή τους κατόχους άλλων κεφαλαιακών μέσων) ή/και στην επιχειρηματική δραστηριότητα, στην οικονομική κατάσταση, στα λειτουργικά αποτελέσματα και στις προοπτικές του Εκδότη”.

3. Οι πληροφορίες που παρατίθενται κατωτέρω συμπληρώνουν την ενότητα 4.1 (Υπό ποιες προϋποθέσεις και χρονοδιάγραμμα μπορώ να επενδύσω στις Νέες Κοινές Μετοχές;) του Περιληπτικού Σημειώματος. Η τελευταία παράγραφος υπό τον τίτλο «Γενικοί όροι και προϋποθέσεις» διαγράφεται στο σύνολό της και αντικαθίσταται ως εξής:

«Εκτός από την Επενδυτική Συμφωνία, όπως παρατίθεται στο Έγγραφο Αναφοράς ο Εκδότης δεν έχει καμία ένδειξη σχετικά με το αν Κύριοι Μέτοχοι ή μέλη των διοικητικών, διαχειριστικών ή εποπτικών οργάνων του Εκδότη προτίθενται να καλύψουν τη Δημόσια Προσφορά, ή αν οποιοδήποτε πρόσωπο προτίθεται να εγγραφεί για περισσότερο από το πέντε τοις εκατό (5%) των Νέων Κοινών Μετοχών.»

4. Οι πληροφορίες που παρατίθενται κατωτέρω συμπληρώνουν την ενότητα 4.1 (Υπό ποιες προϋποθέσεις και χρονοδιάγραμμα μπορώ να επενδύσω στις Νέες Κοινές Μετοχές;) του Περιληπτικού Σημειώματος. Το χρονοδιάγραμμα που συμπεριλαμβάνεται υπό τον τίτλο «Αναμενόμενο Χρονοδιάγραμμα» διαγράφεται στο σύνολό του και αντικαθίσταται ως εξής:

30 Δεκεμβρίου 2022	Έγκριση της Αύξησης από την Έκτακτη Γενική Συνέλευση της Attica Bank
16 Μαρτίου 2023	Έγκριση του Ενημερωτικού Δελτίου από την ΕΚ
16 Μαρτίου 2023	Δημοσίευση της ανακοίνωσης σχετικά με τη διάθεση του Ενημερωτικού Δελτίου στο Ημερήσιο Δελτίο Τιμών του Χ.Α. και στην ιστοσελίδα του Εκδότη.
16 Μαρτίου 2023	Δημοσίευση του Ενημερωτικού Δελτίου
16 Μαρτίου 2023	Έγκριση του Χ.Α. για την έναρξη της διαπραγμάτευσης και την άσκηση των δικαιωμάτων προτίμησης*
16 Μαρτίου 2023	Ανακοίνωση για την ημερομηνία αποκοπής των δικαιωμάτων προτίμησης και για την περίοδο διαπραγμάτευσης και άσκησης των δικαιωμάτων προτίμησης
24 Μαρτίου 2023	Τελευταία ημέρα διαπραγμάτευσης των Υφιστάμενων Κοινών Μετοχών με δικαιώματα προτίμησης
27 Μαρτίου 2023	Αποκοπή των δικαιωμάτων προτίμησης και προσαρμογή της τιμής της μετοχής
28 Μαρτίου 2023	Ημερομηνία καταγραφής για τους δικαιούχους των δικαιωμάτων προτίμησης
29 Μαρτίου 2023	Πίστωση των δικαιωμάτων προτίμησης στους Λογαριασμούς Αξιογράφων των Δικαιούχων
30 Μαρτίου 2023	Έναρξη της διαπραγμάτευσης και άσκηση των δικαιωμάτων προτίμησης
19 Απριλίου 2023	Τελευταία ημέρα της διαπραγμάτευσης δικαιωμάτων προτίμησης
20 Απριλίου 2023	Έγκριση του Συμπληρώματος από την ΕΚ
20 Απριλίου 2023	Δημοσίευση της ανακοίνωσης σχετικά με τη διάθεση του Συμπληρώματος στο Ημερήσιο Δελτίο Τιμών του Χ.Α. και στην ιστοσελίδα του Εκδότη
20 Απριλίου 2023	Δημοσίευση του Συμπληρώματος
21 Απριλίου 2023	Έναρξη άσκησης Δικαιώματος Υπαναχώρησης
24 Απριλίου 2023	Τελευταία ημέρα άσκησης Δικαιώματος Υπαναχώρησης
24 Απριλίου 2023	Τελευταία ημέρα άσκησης των δικαιωμάτων προτίμησης
25 Απριλίου 2023	Κατανομή και διάθεση αδιάθετων Νέων Κοινών Μετοχών
26 Απριλίου 2023	Πιστοποίηση καταβολής της Αύξησης
26 Απριλίου 2023	Ανακοίνωση για την κάλυψη της Αύξησης
27 Απριλίου 2023	Έγκριση του Χ.Α. για την εισαγωγή προς διαπραγμάτευση των Νέων Κοινών Μετοχών*
28 Απριλίου 2023	Έναρξη της διαπραγμάτευσης Νέων Κοινών Μετοχών

*Με την επιφύλαξη της συνεδρίασης της αρμόδιας επιτροπής του Χ.Α. την ημερομηνία αυτή.

1. The information set out below supplements the section of the Registration Document entitled (*Definitions and Glossary*) of the Registration Document. The following new definitions shall be included:

"Investment Agreement"

The investment agreement dated 20 April 2023 between HFSF, Pancreta Bank S.A., Thrivest Holding Ltd and the Issuer regarding, the participation of HFSF, Pancreta Bank S.A. and Thrivest Holding Ltd in the Share Capital Increase and their investment in the Issuer."

"Merger"

The planned merger of the Issuer and Pancreta Bank contemplated under the Investment Agreement by no later than 12 months after the date of such agreement (as such period may be extended by agreement by the parties to reflect any delay in obtaining all required approvals from any competent Authority and potentially third parties, or any other reason) and subject to the condition precedents and terms contained therein including, inter alia, approval by the corporate bodies of the parties to the Investment Agreement and compliance with the HFSF Law as well as the satisfactory completion of financial, tax and legal audit and due diligence by the parties over the two credit institutions.

"Pancreta"

Pancreta Bank S.A., a credit institution with GEMI number 77156527000 and registered seat at Ikarou and Efessou 13 str., Herakleion, Crete, as legally represented. "

"Thrivest"

Thrivest Holding LTD, a limited company incorporated and operating pursuant to the laws of Cyprus, registered under registration number HE-439607, having its registered seat at 81 Griva Digeni str., Marinos court, 3rd floor, Flat/Office 301, CY 6043 Larnaka, Cyprus, as legally represented.

2. The information set out below supplements section 1.1 (*Risks relating to the Issuer's business*) of the Registration Document. The final paragraph of Risk Factor 1. entitled "*Failure to timely meet the applicable regulatory capital ratios through the successful completion of the Share Capital Increase or of any other capital action contemplated in the Business Plan may lead to the implementation of one or more resolution measures and/or the request of public financial support for Attica Bank, which will have a material adverse effect on Shareholders (or holders of other capital instruments) and/or its business, financial condition, results of operations and prospects*" shall be deleted in its entirety and replaced with the following:

"The Issuer expects that a successful completion of the Share Capital Increase will enable the Issuer to significantly increase its regulatory capital ratios whilst decreasing its NPE ratio in accordance with the Business Plan. However, other than the commitments contemplated under the Investment Agreement, there are no commitments nor any guarantee towards the subscription of the New Ordinary Shares and the Public Offering is not subject to an underwriting agreement; accordingly, there can be no assurance that the Share Capital Increase will be subscribed in full or at all. For more information about the Investment Agreement, please refer to section 5.1 "Group's Business Overview" –Overview – Recent Events -Investment Agreement" If the Share Capital Increase is not fully subscribed, the Existing Issued Share Capital will only be increased up to the amount actually subscribed and paid for, in accordance with article 28 paragraph 1 of Law 4548/2018. Failure to raise the equity needed for the restoration of the Issuer's regulatory capital ratios through the Share Capital Increase or future capital actions, may force the regulatory authorities to subject Attica Bank to resolution measures and/or Attica Bank to request public financial support which will have a material adverse effect on its Shareholders (or holders of other capital instruments) and/or its business, financial condition, results of operations and prospects. For more information regarding the Issuer's capital action plans please refer to sections 11.1 "Capital Management" and Section 16 "Profit Forecasts"."

3. The information set out below supplements section 5.1 (*Overview*). The following shall be deemed to be inserted at the end of the paragraph entitled "(4) Key Terms Agreement":

"According to information received by the Issuer from HFSF, the Key Terms Agreement ceases to be in force from the date of signing of the Investment Agreement. "

4. The information set out below supplements section 5.1 (*Overview*). The following shall be deemed to be inserted at the end of the section entitled "*Recent Events*":

"Investment Agreement

*On 20 April 2023, HFSF, Thrivest Holding Ltd ("**Thrivest**" and together with HFSF, the "**Investors**"), Pancreta Bank S.A. ("**Pancreta Bank**") and the Issuer (the "**Investment Agreement Parties**") entered into an investment agreement on the commercial terms for the participation by the HFSF, Thrivest and Pancreta Bank in the Share Capital Increase and their investment in the Issuer (the "**Investment Agreement**"). It should be noted that TMEDE is not party to the Investment Agreement and has notified the Issuer that it is not intending to participate in the Share Capital Increase.*

Pursuant to the Investment Agreement:

- *HFSF, Thrivest and Pancreta Bank are committed to participate in the Share Capital Increase under the provisions of the legislative framework including the HFSF Law as follows:*

(a) the HFSF commits to invest up to €329,000,000 in total, subject to the condition that the Share Capital Increase is fully covered, as per the HFSF Law;

(b) Thrivest commits to invest up to €30,000,000 in total, through acquisition of new shares in the Issuer for which the pre-emption rights were not subscribed subject to the condition that the HFSF exercises its pre-emption rights in the Share Capital Increase in full, and

(c) Pancreta commits to invest up to €34,000,000 in total, through acquisition of new shares in the Issuer for which the pre-emption rights were not subscribed, subject to the condition that the HFSF exercises its pre-emption rights in the Share Capital Increase in full.

It is noted that the non subscription of the Share Capital Increase constitutes a risk factor (see section 1.1 (Risks relating to the Issuer's business - Failure to timely meet the applicable regulatory capital ratios through the successful completion of the Share Capital Increase or of any other capital action contemplated in the Business Plan may lead to the implementation of one or more resolution measures and/or the request of public financial support for Attica Bank, which will have a material adverse effect on Shareholders (or holders of other capital instruments) and/or its business, financial condition, results of operations and prospects).

- *Upon completion of the Share Capital Increase, Thrivest will propose two replacement non-executive members to participate, together with the existing members in the current Board of Directors of the Issuer.*

- *The Parties have agreed to procure upon completion of the Share Capital Increase, a board meeting of the Issuer to convene an extraordinary general meeting to be held immediately after the lapse of the minimum period required under article 122 paragraph 1 of Greek law 4548/2018, with sole item on the agenda the election of a new Board of Directors. The HFSF, Thrivest and Pancreta Bank have agreed to exercise their voting rights in such extraordinary meeting to elect a new BoD consisting of thirteen (13) directors.*

- *The Issuer will implement the NPE reduction strategy approved by the Board of Directors (for more information please refer to sections 5.5 (2022 to 2025 Business Plan) and 6.3 (Asset Quality and NPEs – Next steps with respect to current securitisations). Pancreta Bank will also implement an NPE reduction strategy.*

- *The HFSF and Thrivest have reached an agreement in principle concerning the Merger. The Share Capital Increase will not be affected by the completion or otherwise of the Merger. The exchange ratio will be determined taking into account the valuations to be performed by financial advisors of the Investment Agreement Parties.*

- *Following the Merger and approvals by the corporate bodies of all Investment Agreement Parties, the HFSF (in compliance with the HFSF Law) and Thrivest intend to proceed with a second investment and share*

capital increase (the "**Second Investment**") in the new merged entity (the "**Merged Bank**"). Each of HFSF and Thrivest will participate in the Second Investment in accordance with their individual participation percentage in the Merged Bank and with respect to HFSF in compliance with the HFSF Law.

- It is the intention of the parties that Thrivest will have majority control over the Merged Bank. To this end, the HFSF and Thrivest may issue financial instruments of their common acceptance.

The execution and the terms of the Investment Agreement were approved by the Board of Directors of the Issuer on 19 April 2023.

5. The information set out below supplements section 9.1 (*Major Shareholders*) of the Registration Document. The final paragraph of the section entitled "*Information regarding shares and shareholdings*" shall be deleted in its entirety and replaced with the following:

"Other than the Investment Agreement, Attica Bank is not aware of any arrangement, the operation of which may, at a subsequent date, result in a change in control of Attica Bank. For a description of the Investment Agreement, please refer to section 5.1 "Overview – Recent Events – Investment Agreement."

6. The information set out below supplements section 13 (*Regulatory Disclosures*) of the Registration Document.

- (i) The following new item shall be included at the end of paragraph (b) (*Disclosure related to information from third parties in respect of the Issuer*):

"11 April 2023 – Attica Bank announcement regarding an agreement for the purchase of the junior notes issued under the Metexelixis securitisation.

(For the detailed announcement please refer to: <https://www.atticabank.gr/en/group/news/latest-news/133-announcements/2304-attica-bank-announcement-of-11042023-en>)"

- (ii) The following new item shall be included at the end of paragraph (d) (*Disclosure related to the corporate governance of the Issuer*):

"29 March 2023 – Attica Bank announcement regarding new executives joining the management team.

(For the detailed announcement please refer to: <https://www.atticabank.gr/en/group/news/latest-news/33-announcements/2298-attica-bank-announcement-of-29032023-en>)"

- (iii) The following new items shall be included at the end of paragraph (e) (*Disclosure related to the share capital increase of the Issuer*):

"22 March 2023 – Attica Bank announcement that the Issuer is in continuous and advanced discussions between its main shareholders and Thrivest Holding Ltd.

(For the detailed announcement please refer to: <https://www.atticabank.gr/en/group/news/latest-news/133-announcements/2296-attica-bank-announcement-of-22032023-en>)"

6 April 2023 – Attica Bank announcement that the Issuer has received information concerning an agreement in principle between the Hellenic Financial Stability Fund (HFSF) - the Engineers' Contractors of Public Works Fund (TMEDE) and Thrivest Holding Ltd, which is expected to be reflected in binding legal documentation.

(For the detailed announcement please refer to: <https://www.atticabank.gr/en/group/news/latest-news/133-announcements/2302-attica-bank-announcement-of-06042023-en>)"

20 April 2023 - Attica Bank announcement regarding (i) an Investment Agreement between HFSF, Thrivest Holding Ltd, Pancreta Bank S.A. and Attica Bank regarding, inter alia, the Share Capital Increase (the

"Investment Agreement") and (ii) the Key Terms Agreement ceasing to have effect from the date of signing of the Investment Agreement , following TMEDE's decision to exit the negotiations regarding its participation in the Share Capital Increase.

(For the detailed announcement please refer to: <https://www.atticabank.gr/en/group/news/latest-news/133-announcements/2308-attica-bank-announcement-of-20042023-en>)"

7. The information set out below supplements, and shall be deemed to be inserted at the end of, section 14 (*Material Contracts*) of the Registration Document:

"HFSF, Thrivest Holding Ltd, Pancreta Bank S.A.: an investment agreement dated 20 April 2023 between HFSF, Pancreta Bank S.A., Thrivest Holding Ltd and the Issuer regarding, inter alia, the Share Capital Increase and the Merger."

3 SECURITIES NOTE

1. The information set out below supplements section 5 (*Terms and Conditions*) of the Securities Note.

- (i) The section entitled "*Share Capital Increase*" shall be amended by including the following below the paragraph headed "*Resolutions of the Board held on 16 March 2023*":

"Resolutions of the Board held on 20 April 2023

On 20 April 2023 the Board resolved, inter alia, that the Prospectus be amended by way of a supplement dated 20 April 2023 (the "Prospectus Supplement") and the entry into the Investment Agreement by the Issuer shall be approved."

- (ii) The section entitled "*Withdrawal*" shall be amended by including the below paragraph below the existing paragraph:

"Investors who have already agreed to subscribe for New Ordinary Shares before the date of the Prospectus Supplement shall have the right, exercisable within two (2) working days after the publication of the Prospectus Supplement, to withdraw their subscription for such New Ordinary Shares. The last day on which such right of withdrawal can be exercised shall be 24 April 2023."

- (iii) The section entitled "*Subscription of Public Offering*" shall be amended by deleting in its entirety the sixth paragraph and replacing it with the following:

"Other than the Investment Agreement (as defined below), as disclosed in the Registration Document, the Issuer has no indication of whether the Major Shareholders or members of the Issuer's management, supervisory or administrative bodies intend to subscribe in the Public Offering, or whether any person intends to subscribe for more than five per cent (5%) of the New Ordinary Shares. (For a description of the Investment Agreement, please refer to section 5.1 "Overview – Recent Events – Communications from Major Shareholders and Private Investors – (7) Investment Agreement")."

- (iv) The section entitled "*Subscription of Public Offering*" shall be amended by inserting the following before the final paragraph at the end of such section:

"On 22 March 2023 the Issuer made an announcement on ATHEX that it was in continuous and advanced discussions between its main shareholders and Thrivest Holding Ltd in connection with their potential participation in the Share Capital Increase (see section 13 "Regulatory Disclosures" paragraph "(e) Disclosure related to the share capital increase of the Issuer")."

*On 20 April 2023, HFSF, Thrivest Holding Ltd ("**Thrivest**"), Pancreta Bank S.A. ("**Pancreta Bank**") and the Issuer entered into an investment agreement regarding, inter alia, the Share Capital Increase (the "**Investment Agreement**"). (For a description of the Investment Agreement, please refer to section 5.1 "Overview – Recent Events – Communications from Major Shareholders and Private Investors – (7) Investment Agreement")."*

2. The information set out below supplements section 6 (*Admission to Trading and Dealing Arrangements*) of the Securities Note. The expected indicative timetable for the Public Offering and the Admission shall be deleted in its entirety and replaced with the following:

Date	Event
30 December 2022	EGM approves the Share Capital Increase
16 March 2023	Approval of Prospectus by the HCMC
16 March 2023	Publication of announcement regarding the availability of the Prospectus in the Daily Statistical Bulletin of the ATHEX and on the Issuer's website.
16 March 2023	Publication of the Prospectus
16 March 2023	ATHEX approval for the commencement of trading and exercise of pre-emptive rights*
16 March 2023	Announcement of the date of detachment of the pre-emptive rights and the period of trading and exercise of pre-emptive rights
24 March 2023	Last day of trading of Existing Ordinary Shares with pre-emptive rights
27 March 2023	Detachment of pre-emptive rights and adjustment of share price

28 March 2023	Record date for the beneficiaries of pre-emptive rights
29 March 2023	Crediting of pre-emptive rights on the Securities Accounts of the beneficiaries
30 March 2023	Commencement of trading and exercise of pre-emptive rights
19 April 2023	Last day of trading of pre-emptive rights
20 April 2023	Approval of Prospectus Supplement by the HCMC
20 April 2023	Publication of announcement regarding the availability of the Prospectus Supplement in the Daily Statistical Bulletin of the ATHEX and on the Issuer's website
20 April 2023	Publication of the Prospectus Supplement
21 April 2023	Commencement of exercise of the right of withdrawal
24 April 2023	Last day of exercise of the right of withdrawal
24 April 2023	Last day of exercise of pre-emptive rights
25 April 2023	Allocation and disposal of any unsubscribed New Ordinary Shares
26 April 2023	Certification of payment of the Share Capital Increase
26 April 2023	Announcement on the subscription of the Share Capital Increase
27 April 2023	ATHEX approval for the admission to trading of the New Ordinary Shares *
28 April 2023	Commencement of trading of the New Ordinary Shares

* Subject to the competent ATHEX committee meeting on that date."

3. The information set out below supplements section 8 (*Dilution*) of the Securities Note. The third paragraph and following table shall be deleted in its entirety and replaced with the following:

(a) The table below sets out Attica Bank's shareholding structure after the Share Capital Increase, under the following assumptions: (a) e-EFKA does not exercise its pre-emption rights and does not participate in the Share Capital Increase at all, (b) TMEDE does not exercise its pre-emption rights and does not participate in the Share Capital Increase at all; (c) in accordance with the Investment Agreement the HFSF subscribes for €329 million of New Ordinary Shares, Thrivest subscribes for €30 million of New Ordinary Shares and Pancreta Bank subscribes for €34 million of New Ordinary Shares and (d) any remaining New Ordinary Shares are not subscribed, hence the Share Capital Increase is not subscribed for in full. It is noted that this scenario is hypothetical and based on assumptions which may not come true:

Shareholder ⁽¹⁾	Number of Ordinary Shares	Percentage of Ordinary Shares
HFSF	31,300,851	80.09%
TMEDE	2,005,278	5.13%
Thrivest	2,222,222	5.69%
Pancreta Bank	2,518,518	6.44%
e-EFKA	837,390	2.14%
Other Shareholders (<5%)	198,041	0.51%
Total	39,082,300	100%

⁽¹⁾ One Ordinary Share corresponds to one voting right.

Source: Issuer's analysis – Based on shareholder register as at the date of the Prospectus Supplement.

It is noted that the non subscription of the Share Capital Increase constitutes a risk factor (see section 1.1 (Risks relating to the Issuer's business - Failure to timely meet the applicable regulatory capital ratios through the successful completion of the Share Capital Increase or of any other capital action contemplated in the Business Plan may lead to the implementation of one or more resolution measures and/or the request of public financial support for Attica Bank, which will have a material adverse effect on Shareholders (or holders of other capital instruments) and/or its business, financial condition, results of operations and prospects).

(b) The table below sets out Attica Bank's shareholding structure after the Share Capital Increase, under the following assumptions: (a) e-EFKA does exercise its pre-emption rights with respect to the totality of the Ordinary Shares it holds, (b) TMEDE does not exercise its pre-emption rights and does not participate in the Share Capital Increase at all; (c) The Board of Directors receives and satisfies applications for subscriptions from various new applicants-potential shareholders, covering the total of the unsubscribed shares without exceeding 5% of the Issuer Share Capital for each applicant, and (d) in accordance with the Investment Agreement

the HFSF subscribes for €329 million, Thrivest subscribes for €30 million and Pancreta Bank subscribes for €34 million of New Ordinary Shares, hence the Share Capital Increase is subscribed for in full. It is noted that the above scenario is hypothetical and based on assumptions that may not come true:

<i>Shareholder⁽¹⁾</i>	<i>Number of Ordinary Shares</i>	<i>Percentage of Ordinary Shares</i>
<i>HFSF</i>	<i>31,300,851</i>	<i>69.51%</i>
<i>TMEDE</i>	<i>2,005,278</i>	<i>4.45%</i>
<i>Thrivest</i>	<i>2,222,222</i>	<i>4.93%</i>
<i>Pancreta</i>	<i>2,518,518</i>	<i>5.59%</i>
<i>e-EFKA</i>	<i>3,781,991</i>	<i>8.40%</i>
<i>Other Shareholders (<5%)</i>	<i>3,205,059</i>	<i>7.12%</i>
<i>Total</i>	<i>45,033,921</i>	<i>100%</i>

⁽¹⁾ One Ordinary Share corresponds to one voting right.

Source: Issuer's analysis – Based on shareholder register as at the date of the Prospectus Supplement.

It is noted that the non subscription of the Share Capital Increase constitutes a risk factor (see section 1.1 (Risks relating to the Issuer's business - Failure to timely meet the applicable regulatory capital ratios through the successful completion of the Share Capital Increase or of any other capital action contemplated in the Business Plan may lead to the implementation of one or more resolution measures and/or the request of public financial support for Attica Bank, which will have a material adverse effect on Shareholders (or holders of other capital instruments) and/or its business, financial condition, results of operations and prospects).